Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: VELCADE

« Back to Dashboard

Summary for Tradename: VELCADE

Patents:8
Applicants:1
NDAs:1
Suppliers: see list1
2013 Sales:$621,800,000

Pharmacology for Tradename: VELCADE

Drug ClassProteasome Inhibitor
Mechanism of ActionProteasome Inhibitors

Clinical Trials for: VELCADE

Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease
Status: Completed Condition: Graft-versus-Host Disease

Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma
Status: Terminated Condition: Multiple Myeloma

Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Status: Active, not recruiting Condition: Multiple Myeloma

A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma
Status: Completed Condition: Multiple Myeloma

Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma
Status: Completed Condition: Non-Hodgkin's Lymphoma; Mantle Cell Lymphoma

Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease
Status: Completed Condition: Chronic Graft Versus Host Disease

Low Dose Melphalan and Bortezomib for AML and High-Risk MDS
Status: Completed Condition: Acute Myelogenous Leukemia; Myelodysplastic Syndromes

Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML
Status: Completed Condition: Acute Myelogenous Leukemia

Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)
Status: Completed Condition: Multiple Myeloma

Pilot Study of Velcade® in IgA Nephropathy
Status: Recruiting Condition: Chronic Kidney Disease; IgA Nephropathy

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Millennium Pharms
VELCADE
bortezomib
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602May 13, 2003RXYes6,083,903<disabled>Y<disabled>
Millennium Pharms
VELCADE
bortezomib
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602May 13, 2003RXYes6,617,317<disabled>YY<disabled>
Millennium Pharms
VELCADE
bortezomib
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602May 13, 2003RXYes<disabled><disabled>
Millennium Pharms
VELCADE
bortezomib
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602May 13, 2003RXYes5,780,454<disabled>Y<disabled>
Millennium Pharms
VELCADE
bortezomib
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602May 13, 2003RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: VELCADE

Drugname Dosage Strength RLD Submissiondate
bortezomibFor Injection3.5 mg/vialVelcade11/20/2008
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc